Table 1.
- Basic characteristics of patients in both groups.
| Variable | Empagliflozin (n=45) | Placebo (n=48) | P-value |
|---|---|---|---|
| Age (years) | 55 (45.5–64) | 57 (50–66.75) | 0.370 |
| Gender | |||
| Male | 27 (60.0) | 29 (60.4) | 0.967 |
| Female | 18 (40.0) | 19 (39.6) | |
| Duration of diabetes (years) | 6 (4-8) | 6 (9-2) | 0.753 |
| Smoking | 9 (20.0) | 8 (16.7) | 0.679 |
| Underlying disease | |||
| CKD | 4 (8.9) | 3 (6.3) | 0.632 |
| Hypertension | 26 (57.8) | 32 (66.7) | 0.379 |
| CVA | 1 (2.2) | 2 (4.2) | 0.598 |
| ACS | |||
| STEMI | 27 (60.0) | 23 (50.0) | 0.335 |
| Non-STEMI | 2 (4.4) | 4 (8.3) | 0.448 |
| unstable angina | 16 (35.6) | 21 (43.8) | 0.422 |
| Number of vessels involved | |||
| 1 | 15 (33.3) | 19 (36.6) | 0.543 |
| 2 | 15 (33.3) | 15 (31.3) | |
| 3 | 15 (33.5) | 14 (29.2) | |
The numbers are presented as interquartile range (IQR) or frequency (percentage). Significance level: p<0.05. CKD: chronic kidney disease, CVA: cerebrovascular accident, ACS: acute coronary syndrome, STEMI: ST-elevation myocardial infarction